Cargando…
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
BACKGROUND: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy. However, their use is complicated by immune-related adverse events (irAEs), including endocrine adverse events (eAEs...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bioscientifica Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937198/ https://www.ncbi.nlm.nih.gov/pubmed/29739808 http://dx.doi.org/10.1530/EC-18-0079 |